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Innovations
Microbia
Engineering Microbial Network Biology
named “Anti-Invasin” drug discov- multiplex, high-throughput gene re-
porter screen to look for compoundsery effort to develop a novel class of
antifungal drug. “What we’ve done is that will block invasion. So far, the
As its name implies, Microbia is in
the business of bugs—bacteria and
fungi, that is. This company dons the
roles of both prosecution and advo- exploit new links of physiologies to company has identified several Anti-
Invasin classes with in vitro efficacy.cate for all sorts of microbes in a disease, including those that aren’t
evident in a petri dish,” says Hen-three-pronged systems-based ap- “And we’re enthused to say we have
validated the approach in vivo in ani-proach to developing novel drugs. derson.
“There is significant unmet needFrom its headquarters in the Kendall mal studies,” adds Henderson.
“One of the banes of antifungalSquare technology haven of Cam- for antifungal therapeutics under-
scored by increased systemic infec-bridge, Massachusetts, Microbia’s drug discovery is that it has been
difficult to find specific fungicidal73 employees are lead by a founding tion prevalence rates and mortality
figures in immunocompromised pa-team of ex-Whitehead Institute fel- or -static targets not shared by hu-
man cells,” says Henderson. Thelows now supplemented with pharma tients,” says Henderson. With con-
ventional drugs, he cites data show-execs from Pharmacia, Merck, and company hopes the novel mecha-
nism of attacking these infectiousSepracor. “The founders worked ex- ing 50%–75% mortality in patients
following systemic Aspergillus fumi-tensively in understanding the cellu- pathogens will translate into limited
cross-resistance with other antifun-lar networks involved in bacterial
and fungal pathogenesis and have gals too.
Microbia expects the Anti-Invasinbrought that expertise here,” says “A target or pathway itselfJohn J. Talley, PhD, Vice President program to enter human clinical
isn’t so critical. You haveof Drug Discovery at Microbia. That testing in 2004. Its targeted use is in
immunocompromised populationscomprehensive approach to under- to look at the whole or-
standing disease pathogenesis is at such as oncology, transplant, andganism, not just the cellthe heart of Microbia’s drug design HIV patients and in the ICU. These
processes in isolation, toefficiency efforts. patients often have multiple indwell-
ing lines such as catheters, which“Industry has been seduced by see what the opportuni-
tools like proteomics, genomics, are notorious pathways for infection.ties are.”and high-throughput chemistry, for According to Henderson, the excit-
–John J. Talley, PhD, Viceexample,” explains Talley. “But few ing opportunity related to Anti-Inva-
sin antifungals is their potential usepeople know what to do with all the President of Drug Discov-
information.” It’s what Microbia is alone or in combination with con-ery, Microbianot doing that is so different. Instead ventional therapies to enhance effi-
of focusing on a particular pathway cacy and drive mortality rates down.
or target for its drug design efforts, He also adds that there is another
the company is taking a more mac- market opportunity with prophylac-
gatus infection, an infection oc-roscopic view. “A target or pathway tic therapy in high-risk, immuno-
curring during oncology and in neu-itself isn’t so critical,” adds Talley. compromised patients.
tropenic patients (patients with an“You have to look at the whole or- Other nonsystemic fungal infec-
unexplained fever), and a 40% mor-ganism, not just the cell processes tions, such as vaginal, skin, and nail
tality rate with the more prevalentin isolation, to see what the opportu- infection, are mostly well served by
Candida albicans.nities are.” current therapies. “We intend to pur-
Microbia researchers have dis-“The appeal of network biology sue these indications only as far as
covered that fungal cells can senseis that you’re focusing on the whole treatment for recurrent infections
pH, cAMP, and osmolarity, amongsystem,” says Bart Henderson, Vice that may be refractory or resistant to
other environmental cues, and canPresident of Business Development traditional drugs,” says Henderson.
change their state when conditionsat Microbia. “Cutting a biological “With our Anti-Invasin program,
are right to transition from their cus-process up in pieces can lead you we now have a biological proof of
tomary benign yeast form into an in-to losing sight of the whole system.” principle that this is a novel way to
vasive form to invade tissue andAdds Talley, “What works for us is treat mammals,” says Talley.
cause disease. The invasive form ex-combining the biology, pharmacol- Anti-Biofilm Therapeutics
cretes enzymes, destroying tissues.ogy, and chemistry involved in mak- “The story line with our anti-biofilm
strategy is not dissimilar to the Anti-ing great drugs.” “Our drugs block the transition to an
invasive form, so once the immuneAnti-Invasins Block Tissue Invasins,” according to Peter M.
Hecht, PhD, Microbia cofounder andInvasion system recovers, you are perfectly
competent to clear the infection,”Using its systems philosophy, Mi- CEO. “We use the same systems ap-
proach using our understanding ofcrobia’s lead program is its self- says Talley. Microbia designed a
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the network biology underlying dis- The market opportunities for Mi- duction of industrial molecules pro-
ease with great systems-based crobia’s anti-biofilm therapies are duced in microbes.
chemistry and pharmacology to at- targeted against hard-to-treat or re- By mapping the network of path-
tack these new mechanisms.” In this curring infections in which intrinsic ways governing bacterial physiol-
case, Microbia is developing a novel resistance mechanisms play an im- ogy, Microbia’s engineering program
class of antibacterial drugs. portant role. These include pneumo- efficiently up- and downregulates
“The problem we’re after is in- nia, osteomyelitis (acute or chronic pathways involved in production.
trinsic antibiotic resistance mecha- inflammation of the bone), skin and “Our approach is to precision engi-
nisms,” explains Hecht. “The more soft tissue injury, otitis media, and neer bacterial regulatory networks
commonly discussed form is ac- nosocomial or hospital-originating and apply it to these types of prod-
quired resistance: the genetic bloodstream infections like coagu- ucts to improve productivity in a
changes in the organism that make it lase-negative Staphylococcus and short period of time, without the del-
resistant to antibiotic use.” Instead, Enterococcus species, which both eterious mutations that come with
Microbia is targeting physiological tote a 20%–30% mortality burden traditional methods,” explains Hen-
changes that microorganisms un- among immunocompromised pa- derson. This approach is taking the
dergo when under attack. These tients. “The impact for anti-biofilms company into pharmaceutical and
windows into the biological net- would be to reduce hospital stays fine chemical manufacturing and
works that underlie this problem and mortality,” says Henderson. An- also to the frontier of synthesizing
come from studying biofilms. When other application is for treatment chemicals via “green chemistry”
bacteria are out in the free-floating and prophylaxis of medical device instead of traditional petroleum-
phase, they are floating as single infections. Infected orthopedic im- based chemistry.
cells and are sensitive to antibiotics. plants, though uncommon, require Microbia’s first precision engi-
“But a substantial part of bacterial removal and reimplantation. Vascu- neering partnership, announced in
life involves being hunkered down lar access devices such as indwell- September 2002, is with Teva Phar-
onto surfaces and when threatened, ing catheters have 15% infection maceuticals. Other partnerships will
activating a series of physiological rates. And Pseudomonas infection be announced later in the year. The
changes making them up to 1000- can be a problem with long-wear company is using this program to
fold resistant to antibiotics,” says contact lenses. fund its own drug discovery efforts,”
Hecht. A potential link between bio-
Studies on medical device materi- explains Hecht. “It is a way for us
film production and chronic otitis
als have borne out anti-biofilm effi- to use the same systems approach
media (middle ear) infection was re-
cacy. When implantable devices or that underlies microbial physiol-cently highlighted in the April 3, 2002
materials such as cobalt chromium, ogy,” he says. “In this case, insteadissue of the Journal of the American
the common material for hip im- of crippling the microbes, we’reMedical Association. “What we’ve
plants, and silicone, used in vascular making them into better minifacto-done is to understand the biological
access catheters, were coated with ries to help our partners makenetwork that underlies that physio-
the anti-biofilm therapy MM2137008, money and generate cash for us tological shift and then apply our sys-
S. aureus biofilm formation was in- fund drug discovery.”tems approach to simultaneously
hibited in a dose-dependent way. “Five years from now, we’ll con-target that whole network at once
Bacteria Minifactories and sider our most significant milestonewith systems chemistry to best
Green Chemistry the fusion of network biology, sys-block the process of intrinsic re-
Paradoxically, when Microbia is not tems chemistry, and drug pharma-sistance.”
trying to find new ways to block or cology, ” says Hecht. Adds Talley,In the course of characterizing
kill microbes, it is busy boosting “Our vision is to integrate thosethat network, Microbia researchers
their growth and production effi- three to make a successful organiza-discovered critical elements shared
ciency. “This last part of our pro- tion that loves to make drugs.”between intrinsic resistance and ac-
gram, the precision engineeringquired resistance, such as that seen Chemistry & Biology invites yourtechnology, is not a drug discoveryin methicillin-resistant Staphylococ- comments on this topic. Pleaseprogram, but it is fundamental forcus aureus and vancomycin-resis- write to the editors at chembiol@our business,” says Henderson oftant Enterococcus. “That broadens cell.com.Microbia’s designer microbe pro-the application utility of our thera-
duction technology. “We’re usingpeutics because we can use these Alice A. McCarthy is a freelance science
the same approach for engineeringin combination with other antibiotics writer based in Gloucester, MA (alice@
the regulatory circuitry in microbes alicemccarthy.com).to restore sensitivity, broadening the
to enhance production of pharma-spectrum of these important agents
ceutical and fine chemicals and tothat have become constrained by
synthesize novel chemicals for ouracquired resistance,” says Hecht.
partners.” The underlying goal is toThe company has already presented
improve yields and the manufactur-in vivo data showing that its lead
ing process for these agents. In theanti-biofilm therapeutic, MM2137008,
February 2003 issue of Nature Bio-restores the efficacy of oxacillin
technology, Microbia scientists de-against S. aureus biofilms. A similar
scribed one of their novel ways topotentiation effect has been shown
with MM2137008 and vancomycin. identify genes required for the pro-
